The bottom line, as far as I can tell: $5.6m in cash right now, $1.3m R&D tax refund due. $3m revenue, $5.9m expenditure for a $2.9m loss. So they should be OK for money in the short term. To state the bleeding obvious, if they were able to increase their earnings by a factor of 2 they'd be breaking even.
Interesting that endometriosis gets prominent position early on in the report, we already knew that looked like the next major focus of the company, I think the highlighting just reinforces that.
There's that feeling that I suspect many of you have had for a long time: this is so close to taking off, it just needs all the ducks to get lined up properly.
The bottom line, as far as I can tell: $5.6m in cash right now,...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
35.5¢ |
Change
-0.010(2.74%) |
Mkt cap ! $58.05M | |||
| Open | High | Low | Value | Volume |
| 36.5¢ | 37.0¢ | 35.5¢ | $87.84K | 244.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 63043 | 35.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 72542 | 1 |
View Market Depth
| Last trade - 15.59pm 19/06/2025 (20 minute delay) ? |
| PIQ (ASX) Chart |